Cargando…

Biomarkers for immunotherapy in esophageal cancer

The development of immunotherapy, especially immune-checkpoint inhibitors targeting PD-1/PD-L1, has improved the outcomes of patients with esophageal cancer. However, not all population derives benefit from the agents. Recently, kinds of biomarkers were introduced to predict the response to immunoth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Xuelian, Wang, Ping, Huang, Xiang, Han, Yanan, Zhang, Pei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183563/ https://www.ncbi.nlm.nih.gov/pubmed/37197663 http://dx.doi.org/10.3389/fimmu.2023.1117523

Ejemplares similares

Neoadjuvant immunotherapy for resectable esophageal cancer: A review
por: Li, Qing, et al.
Publicado: (2022)

Immunotherapy resistance in esophageal cancer: Possible mechanisms and clinical implications
por: Fang, Pinhao, et al.
Publicado: (2022)

A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer
por: Ren, Qianhe, et al.
Publicado: (2023)

Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis
por: Liu, Yunsong, et al.
Publicado: (2023)

Editorial: Novel biomarkers for predicting response to cancer immunotherapy
por: Huangfu, Shuchen, et al.
Publicado: (2023)

Predictive biomarkers of colon cancer immunotherapy: Present and future
por: Hou, Wanting, et al.
Publicado: (2022)

Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials
por: Zhu, Jie, et al.
Publicado: (2022)

Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
por: Li, Yueyi, et al.
Publicado: (2023)

GNPNAT1 is a potential biomarker correlated with immune infiltration and immunotherapy outcome in breast cancer
por: Yuan, Renjie, et al.
Publicado: (2023)

Research progress of extracellular vesicles as biomarkers in immunotherapy for non-small cell lung cancer
por: Ge, Yang, et al.
Publicado: (2023)

Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer
por: Li, Shumin, et al.
Publicado: (2020)

Identification and validation of IgG N-glycosylation biomarkers of esophageal carcinoma
por: Pan, Huiying, et al.
Publicado: (2023)

Novel Immune Checkpoints in Esophageal Cancer: From Biomarkers to Therapeutic Targets
por: Zhou, Xueyin, et al.
Publicado: (2022)

Comparison of neoadjuvant immunotherapy versus routine neoadjuvant therapy for patients with locally advanced esophageal cancer: A systematic review and meta-analysis
por: Qin, Hao, et al.
Publicado: (2023)

Small molecule inhibitors for cancer immunotherapy and associated biomarkers – the current status
por: Schlicher, Lisa, et al.
Publicado: (2023)

Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy
por: Damei, Isabelle, et al.
Publicado: (2023)

Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies
por: Trüb, Marta, et al.
Publicado: (2021)

The components of tumor microenvironment as biomarker for immunotherapy in metastatic renal cell carcinoma
por: Su, Jiaming, et al.
Publicado: (2023)

Association of Peripheral Blood Biomarkers With Response to Anti-PD-1 Immunotherapy for Patients With Deficient Mismatch Repair Metastatic Colorectal Cancer: A Multicenter Cohort Study
por: Cheng, Yi-Kan, et al.
Publicado: (2022)

Evaluation of neoadjuvant immunotherapy and traditional neoadjuvant therapy for resectable esophageal cancer: a systematic review and single-arm and network meta-analysis
por: Wang, Hesong, et al.
Publicado: (2023)

Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy
por: Gao, Ran, et al.
Publicado: (2022)

The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis
por: He, Wenwu, et al.
Publicado: (2023)

Editorial: Biomarkers in the era of cancer immunotherapy: zooming in from the periphery to the tumor microenvironment
por: Charo, Jehad, et al.
Publicado: (2023)

The Combination of Radiotherapy With Immunotherapy and Potential Predictive Biomarkers for Treatment of Non-Small Cell Lung Cancer Patients
por: Meng, Lu, et al.
Publicado: (2021)

Safety and Feasibility of Esophagectomy Following Combined Immunotherapy and Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score Matching Analysis
por: Hong, Zhi-Nuan, et al.
Publicado: (2022)

Integrated Profiling Identifies PLOD3 as a Potential Prognostic and Immunotherapy Relevant Biomarker in Colorectal Cancer
por: Shi, Junhong, et al.
Publicado: (2021)

Immune landscape and immunotherapy for penile cancer
por: Tang, Yaxiong, et al.
Publicado: (2022)

Association between immune-related adverse events and the efficacy of PD-1 inhibitors in advanced esophageal cancer
por: Qin, Wenru, et al.
Publicado: (2022)

Identification of OTUD6B as a new biomarker for prognosis and immunotherapy by pan-cancer analysis
por: Zhao, Guang, et al.
Publicado: (2022)

Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures
por: Zhang, Xinke, et al.
Publicado: (2021)

Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
por: Cheng, Jiahan, et al.
Publicado: (2022)

S100A2 Is a Prognostic Biomarker Involved in Immune Infiltration and Predict Immunotherapy Response in Pancreatic Cancer
por: Chen, Yuan, et al.
Publicado: (2021)

Microbiome in cancer: An exploration of carcinogenesis, immune responses and immunotherapy
por: Zhou, Pei, et al.
Publicado: (2022)

Targeted drug delivery system for ovarian cancer microenvironment: Improving the effects of immunotherapy
por: Peng, Hongling, et al.
Publicado: (2022)

Protein Disulfide-Isomerase A3 Is a Robust Prognostic Biomarker for Cancers and Predicts the Immunotherapy Response Effectively
por: Tu, Zewei, et al.
Publicado: (2022)

Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors
por: Zhang, Jiaxin, et al.
Publicado: (2023)

Identification of TREM2-positive tumor-associated macrophages in esophageal squamous cell carcinoma: implication for poor prognosis and immunotherapy modulation
por: Li, Hongmu, et al.
Publicado: (2023)

A pan-cancer and single-cell sequencing analysis of CD161, a promising onco-immunological biomarker in tumor microenvironment and immunotherapy
por: Li, He, et al.
Publicado: (2022)

Mechanism and strategies of immunotherapy resistance in colorectal cancer
por: Shan, Jiqi, et al.
Publicado: (2022)

Organoid Models for Precision Cancer Immunotherapy
por: Sun, Cai-Ping, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7m2ms6ub3nvpvcv9pvueilmv5j